AstraZeneca

MedImmune, is a company that produces Synagis, a drug for the prevention of respiratory infections in infants, which accounted for US$ 1.06 billion of its US$ 1.2 billion in revenue for 2005, and FluMist, a nasal spray influenza vaccine introduced in 2004. MedImmune has over 120 drugs in development for conditions including lupus, COPD, asthma, and many types of cancer.

MedImmune

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AstraZeneca PLC's (LSE:AZN) Imfinzi (durvalumab) has received approval from the U.S. Food and Drug Administration (FDA) as the first immunotherapy treatment for limited-stage small cell lung cancer (LS-SCLC).

US regulator approves AstraZeneca's Imfinzi for small cell lung cancer

The U.S. Food and Drug Administration has approved AstraZeneca blockbuster drug Imfinzi to treat some adults with limited-stage small cell lung cancer, the health regulator said on Wednesday.

FDA approves AstraZeneca's Imfinzi for limited-stage small cell lung cancer

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of AstraZeneca PLC (“AstraZeneca” or the “Company”) (NASDAQ: AZN) investors concerning the Company's possible violations of federal securities laws. On November 5, 2024, news outlets reported that a fraud investigation linked to AstraZeneca had expanded to several Chinese government agencies, implicating dozens of senior executives at the Company. On this news, AstraZeneca's stock price fell $5.1.

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of AstraZeneca PLC (AZN) on Behalf of Investors

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of AstraZeneca PLC (“AstraZeneca” or the “Company”) (NASDAQ: AZN) investors concerning the Company's possible violations of the federal securities laws. If you suffered a loss on your AstraZeneca investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securitie.

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of AstraZeneca PLC (AZN) on Behalf of Investors

AstraZeneca said on Wednesday Iskra Reic will become its new international executive vice president succeeding Leon Wang, who was detained by Chinese authorities in October.

AstraZeneca names new international Executive VP to succeed Leon Wang

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of AstraZeneca PLC (“AstraZeneca” or the “Company”) (NASDAQ: AZN) on behalf of investors concerning the Company's possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. On November 5, 2024, news outlets reported that a fraud investigation linked to AstraZeneca had expanded to several Chinese government agencies, implicating dozens of senior.

The Law Offices of Frank R. Cruz Announces Investigation of AstraZeneca PLC (AZN) on Behalf of Investors

Amazon

Taiwan Semiconductor Manufacturing

Finding the “best” growth stocks to buy really is a subjective task, isn't it?

3 Best Growth Stocks To Buy Now

NEW YORK, NY / ACCESSWIRE / December 3, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of AstraZeneca PLC ("AstraZeneca PLC") (NASDAQ:AZN) concerning possible violations of federal securities laws. On November 5, 2024, the Chinese news outlet Yicai reported that a fraud investigation into AstraZeneca has expanded to include several agencies of the Chinese government, implicating dozens of senior executives at the Company.

Investors who lost money on AstraZeneca PLC should contact Levi & Korsinsky about an ongoing investigation - AZN

Novo Nordisk

Success in 2025 for the pharma sector will hinge on the success of key drug pipeline developments, according to JPMorgan's latest research. With concerns over US drug pricing policies easing and significant patent expirations on the horizon, the focus shifts to pipeline progress to drive growth, the American investment bank reckons, And it says Novo Nordisk (NYSE:NVO) and AstraZeneca PLC (LSE:AZN) are set to lead the way, bolstered by strong mid-term growth and promising news flow.

Novo Nordisk and AstraZeneca top of the 2025 drug picks for US investment bank - read why

Eli Lilly

Pfizer

Leading vaccine makers like Eli Lilly and Co. NYSE: LLY, Pfizer Inc. NYSE: PFE, and AstraZeneca plc NASDAQ: AZN may have faded from the spotlight since the peak of the COVID-19 pandemic, but now there is reason to expect renewed interest. As investors look ahead to the second Trump administration, the incoming president's nomination of outspoken vaccine critic Robert F.

Eli Lilly, Pfizer, and AstraZeneca: 2025 Vaccine Makers to Watch

AstraZeneca's blockbuster breast cancer drug will be added to China's national reimbursement scheme list, according to an update from the National Healthcare Security Administration.

AstraZeneca's Enhertu included in China's state insurance reimbursement

AstraZeneca's Fasenra, an injectable treatment for severe asthma, is more effective during attacks than the oral steroid that has been the standard of care for 50 years, cutting the need for further treatment by 30%, according to a study published on Wednesday.

AstraZeneca asthma drug more effective during attack than steroids, study finds

NEW YORK, NY / ACCESSWIRE / November 26, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of AstraZeneca PLC ("AstraZeneca PLC") (NASDAQ:AZN) concerning possible violations of federal securities laws. On November 5, 2024, the Chinese news outlet Yicai reported that a fraud investigation into AstraZeneca has expanded to include several agencies of the Chinese government, implicating dozens of senior executives at the Company.

Shareholder Rights Advocates at Levi & Korsinsky Investigate AstraZeneca PLC (AZN) Regarding Possible Securities Fraud Violations

Data from a late-stage study shows that treatment with a three-drug combo involving AZN's Truqap benefits patients with an aggressive form of prostate cancer.

AstraZeneca's Combination Therapy Meets Goal in Prostate Cancer Study

NEW YORK, NY / ACCESSWIRE / November 25, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of AstraZeneca PLC ("AstraZeneca PLC") (NASDAQ:AZN) concerning possible violations of federal securities laws. On November 5, 2024, the Chinese news outlet Yicai reported that a fraud investigation into AstraZeneca has expanded to include several agencies of the Chinese government, implicating dozens of senior executives at the Company.

AstraZeneca PLC Being Investigated on Behalf of AstraZeneca PLC Investors Contact Levi & Korsinsky For Details

AstraZeneca PLC (AZN) Shareholders May Have Been Affected by Fraud - Levi & Korsinsky Investigates

AstraZeneca PLC's (LSE:AZN) Truqap (capivasertib) has shown promising results in a trial for aggressive prostate cancer, improving progression-free survival when combined with standard therapies. The phase III CAPItello-281 trial tested Truqap with abiraterone and androgen deprivation therapy (ADT) against a placebo combination in patients with PTEN-deficient metastatic hormone-sensitive prostate cancer, a form of the disease associated with poor outcomes.

AstraZeneca prostate cancer drug shows promising phase III results

NEW YORK, NY / ACCESSWIRE / November 22, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of AstraZeneca PLC ("AstraZeneca PLC") (NASDAQ:AZN) concerning possible violations of federal securities laws. On November 5, 2024, the Chinese news outlet Yicai reported that a fraud investigation into AstraZeneca has expanded to include several agencies of the Chinese government, implicating dozens of senior executives at the Company.

Lost Money on AstraZeneca PLC (AZN)? Contact Levi & Korsinsky Regarding an Ongoing Investigation

An Investigation Has Commenced on Behalf of AstraZeneca PLC Shareholders. Contact Levi & Korsinsky to Discuss Your AZN Losses

Dollar Tree

3 Growth Stocks Trading Near Their 52-Week Lows to Buy Right Now

NEW YORK, NY / ACCESSWIRE / November 20, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of AstraZeneca PLC ("AstraZeneca PLC") (NASDAQ:AZN) concerning possible violations of federal securities laws. On November 5, 2024, the Chinese news outlet Yicai reported that a fraud investigation into AstraZeneca has expanded to include several agencies of the Chinese government, implicating dozens of senior executives at the Company.

AstraZeneca PLC Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your Rights - AZN

Levi & Korsinsky Reminds Shareholders of an Investigation into AstraZeneca PLC (AZN) Regarding Potential Securities Fraud Allegations

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca today pledged $3.5 million to nonprofit organizations across the US as part of Accelerate Change Together (ACT) on Health Equity, an initiative to improve access, affordability and outcomes for patients in urban, suburban and rural communities. This brings the total contributions from the program to more than $15 million to date. Now in its fourth year, ACT on Health Equity will fund 53 nonprofit programs which aim to improve access to healthcare,.

AstraZeneca awards $3.5M for projects to improve access to healthcare for patients across the US

UBS has upgraded AstraZeneca PLC (LSE:AZN) to a 'neutral' rating from 'sell' while maintaining its 12-month price target of 11,300 pence. The change follows a 24% drop in AZ's share price over three months, triggered by ongoing investigations in China and disappointing trial data for its cancer drug Dato-DXd.

AstraZeneca upgraded by leading investment bank, but challenges remain - here's why

AstraZeneca PLC (LSE:AZN) and Daiichi Sankyo said they are 'disappointed and disagree' with a decision by the UK medicines regulator not to give the green light to a breast cancer drug they jointly developed. Talks to approve Enhertu for NHS used collapsed over pricing and despite the intervention of Wes Streeting, the health secretary.

News for AstraZeneca Stock (AZN)